BRPI1012539A2 - composições farmacêuticas - Google Patents

composições farmacêuticas

Info

Publication number
BRPI1012539A2
BRPI1012539A2 BRPI1012539A BRPI1012539A BRPI1012539A2 BR PI1012539 A2 BRPI1012539 A2 BR PI1012539A2 BR PI1012539 A BRPI1012539 A BR PI1012539A BR PI1012539 A BRPI1012539 A BR PI1012539A BR PI1012539 A2 BRPI1012539 A2 BR PI1012539A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
BRPI1012539A
Other languages
English (en)
Portuguese (pt)
Inventor
Saeko Uchida
Teisuke Takahashi
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of BRPI1012539A2 publication Critical patent/BRPI1012539A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1012539A 2009-04-16 2010-04-16 composições farmacêuticas BRPI1012539A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009100210 2009-04-16
PCT/JP2010/057196 WO2010119990A1 (en) 2009-04-16 2010-04-16 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BRPI1012539A2 true BRPI1012539A2 (pt) 2016-03-29

Family

ID=42982643

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012539A BRPI1012539A2 (pt) 2009-04-16 2010-04-16 composições farmacêuticas

Country Status (30)

Country Link
US (1) US20120040898A1 (sr)
EP (3) EP2829271A3 (sr)
JP (4) JP5077786B2 (sr)
KR (2) KR20120016051A (sr)
CN (7) CN105434430A (sr)
AR (1) AR076317A1 (sr)
AU (1) AU2010237748B2 (sr)
BR (1) BRPI1012539A2 (sr)
CA (1) CA2755392A1 (sr)
CY (2) CY1114703T1 (sr)
DK (2) DK2419097T3 (sr)
ES (2) ES2431300T3 (sr)
HK (6) HK1217302A1 (sr)
HR (2) HRP20131120T1 (sr)
ME (2) ME01555B (sr)
MX (1) MX2011010901A (sr)
MY (3) MY183793A (sr)
NZ (4) NZ595314A (sr)
PH (3) PH12015500235A1 (sr)
PL (2) PL2601949T3 (sr)
PT (2) PT2419097E (sr)
RS (2) RS53056B (sr)
RU (2) RU2532330C2 (sr)
SG (6) SG2014012405A (sr)
SI (2) SI2419097T1 (sr)
SM (1) SMT201500015B (sr)
TW (3) TW201500043A (sr)
UA (2) UA105216C2 (sr)
WO (1) WO2010119990A1 (sr)
ZA (1) ZA201106727B (sr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
KR20110118668A (ko) 2009-02-13 2011-10-31 베링거 인겔하임 인터내셔날 게엠베하 1형 당뇨병, 2형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 sglt­2 억제제
SI2486029T1 (sl) 2009-09-30 2015-10-30 Boehringer Ingelheim International Gmbh Postopki za pripravo z glukopiranozilom substituiranih benzil-benzenskih derivatov
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201101809A1 (tr) * 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2872021C (en) 2012-05-17 2022-08-16 Transtech Pharma, Llc Glucokinase activator compositions for the treatment of diabetes
AU2013309904A1 (en) * 2012-08-30 2015-03-19 Taisho Pharmaceutical Co., Ltd. Combinations of SGLT 2 inhibitors and antihypertensive drugs
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HUE041709T2 (hu) 2013-04-05 2019-05-28 Boehringer Ingelheim Int Az empagliflozin terápiás alkalmazásai
AU2014255727B2 (en) 2013-04-18 2019-07-25 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
PL3263134T3 (pl) * 2015-02-27 2021-10-18 The Asan Foundation Kompozycja do zapobiegania lub leczenia zwapnienia zastawek zawierająca inhibitor dpp-4
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法
JP2019531320A (ja) 2016-10-19 2019-10-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ssao/vap−1阻害剤とsglt2阻害剤とを含む組合せ、その使用
CN109922813A (zh) 2016-11-10 2019-06-21 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
WO2018086126A1 (zh) * 2016-11-14 2018-05-17 高雄医学大学 一种检测糖代谢异常的方法及其预防及治疗
EP3781166A1 (en) 2018-04-17 2021-02-24 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
KR20190137343A (ko) 2018-06-01 2019-12-11 김유찬 계량 인덕션
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
WO2020089025A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
ES2967359T3 (es) 2018-10-29 2024-04-29 Boehringer Ingelheim Int Derivados piridinil-sulfonamida, composiciones farmacéuticas y usos de los mismos
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
JP2003520759A (ja) 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
CA2442917C (en) * 2001-04-04 2011-02-01 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
ATE318272T1 (de) * 2001-04-11 2006-03-15 Bristol Myers Squibb Co Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
EP2036901B1 (en) * 2006-06-29 2013-05-01 Taisho Pharmaceutical Co., Ltd C-phenyl 1-thioglucitol compound
JP5194588B2 (ja) * 2006-07-06 2013-05-08 大正製薬株式会社 1−チオ−d−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
CA2656847A1 (en) * 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
AR063627A1 (es) * 2006-11-09 2009-02-04 Boehringer Ingelheim Int Terapia combinada con inhibidores de sgl t-2 y sus composiciones farmaceuticas
AU2007332476A1 (en) * 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. 1-phenyl 1-thio-D-glucitol derivative
CL2008002425A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo

Also Published As

Publication number Publication date
HRP20131120T1 (hr) 2013-12-20
UA111742C2 (uk) 2016-06-10
NZ595314A (en) 2013-03-28
AR076317A1 (es) 2011-06-01
US20120040898A1 (en) 2012-02-16
UA105216C2 (en) 2014-04-25
SG175154A1 (en) 2011-11-28
CN105477639A (zh) 2016-04-13
EP2419097A4 (en) 2012-09-05
HK1217434A1 (zh) 2017-01-13
HK1217435A1 (zh) 2017-01-13
PT2419097E (pt) 2013-10-03
EP2419097A1 (en) 2012-02-22
ME02015B (me) 2015-05-20
WO2010119990A1 (en) 2010-10-21
HRP20141080T1 (hr) 2015-01-02
RS53056B (sr) 2014-04-30
TW201103534A (en) 2011-02-01
SMT201500015B (it) 2015-03-05
MY156679A (en) 2016-03-15
PH12015500235B1 (en) 2015-12-02
NZ623838A (en) 2015-09-25
MY182720A (en) 2021-02-03
JP5910711B2 (ja) 2016-04-27
SG2014012553A (en) 2014-05-29
EP2829271A3 (en) 2015-05-27
CA2755392A1 (en) 2010-10-21
SG2014012462A (en) 2014-05-29
RU2532330C2 (ru) 2014-11-10
KR20120016051A (ko) 2012-02-22
SI2419097T1 (sl) 2014-01-31
EP2601949A3 (en) 2013-09-18
JP6066144B2 (ja) 2017-01-25
ES2523408T3 (es) 2014-11-25
CN102395364A (zh) 2012-03-28
HK1218881A1 (zh) 2017-03-17
ZA201106727B (en) 2012-11-28
ME01555B (me) 2014-04-20
MX2011010901A (es) 2011-11-01
ES2431300T3 (es) 2013-11-25
PH12019500959B1 (en) 2020-06-29
CN105343059A (zh) 2016-02-24
PH12015500235A1 (en) 2015-12-02
HK1217301A1 (zh) 2017-01-06
JP5077786B2 (ja) 2012-11-21
DK2419097T3 (da) 2013-10-28
AU2010237748B2 (en) 2014-10-30
EP2829271A2 (en) 2015-01-28
JP2015063543A (ja) 2015-04-09
HK1217302A1 (zh) 2017-01-06
AU2010237748A1 (en) 2011-10-20
CN105434430A (zh) 2016-03-30
DK2601949T3 (da) 2015-01-05
JP2013006854A (ja) 2013-01-10
CY1114703T1 (el) 2016-10-05
PL2601949T3 (pl) 2015-04-30
SG2014015093A (en) 2014-04-28
CN105343880A (zh) 2016-02-24
JP2012524710A (ja) 2012-10-18
JP2016104775A (ja) 2016-06-09
RU2011146335A (ru) 2013-05-27
JP5660094B2 (ja) 2015-01-28
PH12019500961B1 (en) 2020-08-03
SI2601949T1 (sl) 2014-12-31
PH12019500961A1 (en) 2020-08-03
PT2601949E (pt) 2014-11-12
TW201500043A (zh) 2015-01-01
HK1218871A1 (zh) 2017-03-17
EP2601949B1 (en) 2014-10-29
MY183793A (en) 2021-03-16
PL2419097T3 (pl) 2014-02-28
NZ606888A (en) 2014-07-25
EP2419097B1 (en) 2013-09-25
CN105343060A (zh) 2016-02-24
PH12019500959A1 (en) 2020-06-29
SG2014014807A (en) 2014-05-29
NZ710575A (en) 2016-06-24
EP2601949A2 (en) 2013-06-12
TW201622720A (zh) 2016-07-01
RU2014121260A (ru) 2015-12-10
CY1115907T1 (el) 2017-01-25
RS53761B1 (sr) 2015-06-30
KR20150046382A (ko) 2015-04-29
CN105343871A (zh) 2016-02-24
SG2014012405A (en) 2014-05-29

Similar Documents

Publication Publication Date Title
BRPI1012539A2 (pt) composições farmacêuticas
DK3097925T3 (da) Farmaceutisk sammensætning
LT3061445T (lt) Labai koncentruotos farmacinės kompozicijos
BRPI1004940A2 (pt) composição farmacêutica
SMT201600350B (it) Composizioni farmaceutiche
SMT201700095B (is) Composizioni farmaceutiche per inalazione
SMT201700008B (it) Composizione farmaceutica
DK2395834T3 (da) Natriumnitrit-holdige farmaceutiske sammensætninger
DK3078664T3 (da) Antiparasitiske dihydroazol-sammensætninger
EP2488022A4 (en) Compositions
EP2451274A4 (en) Pharmaceutical compositions
UY33161A (es) Composiciones plaguicidas
BRPI1015939A2 (pt) composição farmacêutica
DK3246018T3 (da) Farmaceutisk sammensætning
SMT201400069B (it) Formulazione farmaceutica
BR112012012108A2 (pt) composição farmacêutica compreendendo propofol
DOP2011000396A (es) Composiciones novedosas
IT1394400B1 (it) Composizioni farmaceutiche
BRPI1010690A2 (pt) composições
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
EE201300005A (et) Ravimkoostis
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
CO6801722A2 (es) Composiciones farmacéuticas
BRPI0922653A2 (pt) preparação farmacêutica
BR112012001340A2 (pt) composições farmacêuticas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]